Suppression of transforming growth factor-β effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor by Sapitro, Jennifer et al.
Suppression of transforming growth factor-β effects in rabbit
subconjunctival fibroblasts by activin receptor-like kinase 5
inhibitor
Jennifer Sapitro,1 Jeffrey J. Dunmire,1 Sarah E. Scott,1 Vijay Sutariya,2 Werner J. Geldenhuys,2
Michael Hewit,3 Beatrice Y.J.T. Yue,4 Hiroshi Nakamura1,2
1Department of Ophthalmology, Summa Health System, Akron, OH; 2Department of Pharmaceutical Sciences, Northeastern Ohio
Universities Colleges of Medicine and Pharmacy, Rootstown, OH; 3Department of Behavioral and Community Health Sciences,
Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH; 4Department of Ophthalmology and Visual
Sciences, University of Illinois at Chicago, College of Medicine, Chicago, IL
Purpose:  Transforming  growth  factor-β  (TGF-β)  activity  has  been  implicated  in  subconjunctival  scarring  in  eyes
following glaucoma filtration surgery (GFS). The purpose of this study is to determine whether an inhibitor for activin
receptor-like kinase (ALK) 5 (also known as TGF-β receptor type I) could suppress TGF-β activity and thereby promote
filtering bleb survival after GFS in a rabbit model.
Methods: An ALK-5 inhibitor, SB-505124, was used. A docking study was performed to investigate the interaction
between the inhibitor and the receptor. Immunofluorescence for connective tissue growth factor (CTGF) and α-smooth
muscle actin (α-SMA) was performed in cultured rabbit subconjunctival fibroblasts. Immunoblotting for phosphorylated
Smad2 (pSmad2), CTGF, and α-SMA was also performed. In an in vivo rabbit GFS model, SB-505124 was delivered in
a lactose tablet during surgery. Eyes were examined by slit-lamp and intraocular pressure (IOP) was measured until the
time of bleb failure or up to 28 days after surgery. Tissue sections on day 5 after surgery were histologically evaluated
after staining with hematoxylin and eosin. The sections were also immunostained for CTGF and α-SMA. In addition, cell
outgrowth from dissected subconjunctival tissues placed in a cell culture flask with media was investigated.
Results: The docking study indicated hydrogen bond interactions between SB-505124 and amino acids His-283 and
Ser-280 of ALK-5.  Suppression of pSmad2,  CTGF,  and α-SMA  by SB-505124  was observed in cultured fibroblasts.  
Filtering blebs in the GFS with SB-505124 group were maintained for more than 10 days, and the period of bleb survival
was significantly longer than that in controls. IOP levels after surgery seemed to be related to bleb survival. Histologically,
subconjunctival cell  infiltration  and scarring at  the surgical site  in the GFS  with SB-505124  and  mitomycin C  (MMC)
groups were much subsided  compared  to  controls.    Suppression  of  CTGF  and  α-SMA  by  SB-505124  was 
also  observed  by immunofluorescence. Cell outgrowth from  explants dissected from eyes to which SB-505124 was 
applied during GFS was robust while outgrowth was poor from those treated with MMC.
Conclusions: The ALK-5 inhibitor SB-505124 was efficacious both in vitro and in vivo in suppressing the TGF-β action.
The inhibitor may provide a novel therapy for preventing ocular inflammation and scarring.
Transforming  growth  factor-β  (TGF-β),  a  family  of
structurally  related  multifunctional  cytokines,  has  a  wide
range  of  biologic  functions  including  cell  growth,
differentiation,  apoptosis,  and  fibrogenesis  [1-3].  TGF-β
typically is secreted in a latent form and is activated through
a complex process of proteolytic activation and dissociation
of latency protein subunits [4,5]. TGF-β has emerged as a key
mediator  of  the  fibrotic  response  to  wounding.  It  is
upregulated during different types of wound healing in tissues
including the eye, liver and skin [3,6-8]. In the eye, TGF-β has
been shown to be important in scarring in conditions such as
proliferative vitreoretinopathy [9], cataract formation [10],
corneal opacities [11], and choroidal neovasculaization [12,
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13] as well as in subconjunctival scarring, a complication of
filtration surgery in glaucoma [14,15]. TGF-β1 and TGF-β2
are expressed in the filtering bleb after glaucoma filtration
surgery (GFS) while TGF- β2 is the predominant form in the
aqueous humor [16,17].
In GFS, postoperative scarring at the wound site is a
critical determinant of the surgical outcome [18,19]. Although
anti-scarring  agents  such  as  mitomycin  C  (MMC)  and  5-
fluorouracil can prevent post-operative scarring and improve
surgical outcome [20,21], they cause widespread fibroblast
cell  death  and  are  associated  with  severe  and  potentially
blinding complications [22,23]. The central role of TGF-β in
wound repair has led to other strategies [13] such as the use
of  anti-TGF-β  antibody  [24,25]  and  antisense
oligonucleotides/siRNA [26,27] to block the TGF-β action. A
monoclonal antibody for TGF-β2, called CAT-152, which
neutralizes TGF-β function, was investigated as an adjunct in
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1880preventing  scar  formation  following  GFS.  However,  in  a
phase  III  clinical  trial,  there  was  no  difference  between
CAT-152 and a placebo in preventing the failure of primary
trabeculectomy  in  human  glaucoma  eyes  [28].  Antisense
oligonucleotides and siRNA for TGF-β or TGF-β receptors
type II have also been investigated for silencing of the gene
expression [26,27]. Although their ability to suppress scarring
was reported in vitro and in vivo, their working period and
stability  may  not  be  suitable  for  clinical  applications.
Moreover, there may also be complications from a general
knockdown of gene expression.
Receptors  and  kinases  are  generally  believed  to  be
effective targets for selectively blocking signaling pathways
in a variety of biologic systems [29,30]. Members of the TGF-
β  superfamily,  i.e.,  TGF-βs,  activin,  myostatin,  and  bone
morphogenetic proteins, bind to type I and type II serine/
threonine  kinase  receptors  and  transduce  intracellular
signaling  through  Smad  proteins.  There  are  seven  known
mammalian  type  I  receptors,  activin  receptor-like  kinase
(ALK)  1–7,  and  five  type  II  receptors  [31,32].  Unique
combinations  of  the  type  I  and  type  II  receptors  confer
specificity of ligand signaling. TGF-βs display a high affinity
for the type II receptors and do not interact with the isolated
type  I  receptors  [4,33].  Signal  transduction  of  TGF-βs  is
initiated  by  binding  to  type  II  receptor,  followed  by  its
association with ALK-5 (also called TGF-β receptor type I).
The activated ALK-5 in turn phosphorylates and activates
transcription factors Smad2/3 [4,5]. TGF-β type II receptor
and ALK-5 should therefore be reliable targets to block the
TGF-β signaling pathway.
Recently,  ALK-5  inhibitors,  that  selectively  block
ALK-5  as  well  as  ALK-4/7,  which  share  similarity  with
ALK-5 in their kinase domains [32], have been described in
several publications to be effective suppressors of TGF-β
activity [34-41]. In experiments described herein, the ALK-5
inhibitor SB-505124 induced a marked reduction in levels of
phosphorylated Smad2 (pSmad2) and downstream proteins of
TGF-β, connective tissue growth factor (CTGF) and α-smooth
muscle  actin  (α-SMA),  in  cultured  rabbit  subconjunctival
fibroblasts. In addition, in an in vivo rabbit GFS model, it was
shown that SB-505124 extended the period of filtering bleb
survival and its toxicity was substantially lower than that of
MMC.
METHODS
Docking study: The interaction between SB-505124 and the
kinase ALK-5 was investigated using computational docking
software. The starting point for this study was to use the well
known  GOLD  docking  software  (version  4.1;  Cambridge
Crystallographic  Center,  Cambridge,  UK),  which  uses  a
genetic algorithm for finding a docking pose, i.e., mode of
binding of compound to the protein. The protein X-ray crystal
structure of ALK-5, 1VJY.pdb, was downloaded from the
Protein Data Bank and prepared for the docking study, using
the  standard  protocols  which  are  set-up  in  GOLD.  These
include separation of the co-crystallized ligand and protein,
as well as addition of the hydrogens to the protein, which are
omitted  in  the  protein  databank  files.  SB-505124  was
computationally drawn using MarvinSketch (version 3.5.4).
Before this compound could be docked into ALK-5 using
GOLD, it had to be rearranged in 3-D to find a biologically
suitable starting point, which is that of an energy minimized
form  of  the  compound.  To  do  this,  MOE  (Chemical
Computing  Croup,  Montreal,  Canada)  was  used,  with  the
following set-up: force-field was MMFF94, termination was
0.001 kcal/mol. Using the kinase scoring function in GOLD,
a suitable docking pose was identified for SB-505124 with
ALK5.
Cell culture: Fresh eyes, including intact conjunctiva with
palpebral  margins,  enucleated  from  New  Zealand  White
(NZW)  rabbits  were  obtained  from  Pel-Freez  Biologicals
(Rogers, AR). Subconjunctival fibroblasts were cultured from
subconjunctival tissues, called tenon’s membrane, dissected
from  rabbit  eyes.  The  cells  were  maintained  in  serum-
containing media and were passaged as previously described
[42].  Third  to  fifth  passages  of  cells  were  used  for
experiments.
Treatment  with  TGF-β2,  inhibitor  and  MMC:  Fibroblasts
were pre-treated with various concentrations of ALK inhibitor
SB-505124 for 1 h and were then incubated for 48 h after 2
ng/ml of TGF-β2 (R&D Systems, Minneapolis, MN) was
added. Controls that were not treated with the inhibitor but
were treated with or without TGF-β2 were also prepared. To
examine whether SB-505124 causes cell death, cells (100%
confluent) in 12-well plates were pre-treated with SB-505124
(10 µM) for 1 h and were then incubated for 48 h after 2 ng/
ml of TGF-β2 was added. Controls that were treated with
0.04% MMC (Kyowa Hakko Kirin, Tokyo, Japan) were also
examined. Cells were treated in 0.04% MMC for 5 min and
were then incubated with 2 ng/ml of TGF-β2 for 48 h after
MMC removal. The number of cells was counted using a
hemocytometer  (Hausser  Scientific,  Horsham,  PA)  after
trypsinization.
Western blotting: After treatment, fibroblasts were lysed in a
RIPA lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA,
1% Triton X-100) for blotting of pSmad2 or in a lysis buffer
(CelLytic M Cell Lysis Reagent; Sigma, St. Louis, MO) for
blotting  of  CTGF  and  α-SMA.  Equal  amounts  of  protein
(20 μg/lane) were resolved on 10% sodium dodecyl sulfate
(SDS)-polyacrylamide  gels.  The  proteins  were  then
transferred  to  PVDF  membranes  (Bio-Rad  Laboratories,
Hercules,  CA)  for  probing  with  monoclonal  rabbit  anti-
pSmad2 (1:500; Millipore, Billerica, MA) followed by HRP-
conjugated  goat  anti-rabbit  IgG  (1:20,000;  Santa  Cruz
Biotechnology,  Santa  Cruz,  CA),  monoclonal  rabbit  anti-
Smad2 (1:500; Invitrogen, Carlsbad, CA) followed by HRP-
conjugated  goat  anti-rabbit  IgG  (1:25,000;  Santa  Cruz
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Cruz Biotechnology) followed by HRP-conjugated donkey
anti-goat  IgG  (1:10,000;  Jackson  ImmunoResearch,  West
Grove,  PA)  or  monoclonal  mouse  anti-α-SMA  (1:4,500;
Sigma) followed by HRP-conjugated goat anti-mouse IgG
(1:100,000;  Jackson  ImmunoResearch).  The  signal  was
detected by enhanced chemiluminescence. In CTGF and α-
SMA  blotting,  the  blots  were  also  probed  with  HRP-
conjugated  monoclonal  mouse  anti-β-Actin  (1:50,000;
Sigma) or mouse anti-GAPDH (1:2,500; Novus Biologicals,
Littleton, CO) followed by HRP-conjugated goat anti-mouse
IgG  (1:75,000)  to  control  for  equal  protein  loading.
Densitometry  was  performed  using  Kodak  Molecular
Imaging Software version 4.5 (Carestream Health, Rochester,
NY). The band intensity of pSmad2, CTGF or α-SMA was
normalized against that of Smad2, β-actin, or glyceraldehyde
3-phosphate dehydrogenase (GAPDH).
Immunocytochemistry:  Subconjunctival  fibroblasts  were
cultured on 8-well chamber slides. After inhibitor and TGF-
β2  treatment,  fibroblasts  were  fixed  with  4%
Figure 1. Docking results of SB-505124
(atom  colors)  in  the  ALK-5  ATP-
binding pocket. The main interactions
between SB-505124 and ALK-5 were
seen  to  be  between  His-283  and
Ser-280, which is located at the ATP
binding site in the intracellular ALK-5
kinase  domain.  Additionally,  a  water
molecule  seems  to  form  a  hydrogen-
bonding bridge between SB-505124 and
amino  acids  Asp-351,  Glu-245  and
Tyr-249. Also shown is the overlay of a
1,5-naphthyridine compound which is
(in green) co-crystallized with ALK-5.
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1882paraformaldehyde  and  permeabilized.  Cells  were  then
incubated with polyclonal goat anti-CTGF (1:100) followed
by Alexa Fluor donkey anti-goat IgG (10 µg/ml; Invitrogen)
or monoclonal mouse anti-α-SMA (1:400) followed by Alexa
Fluor goat anti-mouse IgG (10 µg/ml). Slides were mounted
with  aqueous  mounting  medium  with  4’,6-diamidino-2-
phenylindole  (DAPI)  and  viewed  by  fluorescence
microscopy.
Rabbit GFS model: The experimental protocol was approved
by  the  Institutional  Animal  Care  and  Use  Committee  at
Northeastern  Ohio  Universities  Colleges  of  Medicine  and
Pharmacy.  Animal  care  guidelines  comparable  to  those
published by the US Public Health Service were followed.
Figure 2. Effects of SB-505124 on cell
density.  Rabbit  subconjunctival
fibroblasts were incubated with 10 µM
of SB-505124 or 0.04% MMC and then
with or without TGF-β2 (2 ng/ml) in 12-
well plates for 48 h (n=3).The number
of  cells  was  counted  using  a
hemocytometer after trypsinization. A
reduction in cell number or cell loss was
not observed with or without TGF-β2 in
the  SB-505124,  but  was  seen  in  the
MMC  treatment  group  .  Asterisks
indicate significant difference (p<0.05,
Bonferroni multiple comparison).
Figure  3.  Western  blotting  for
phosphorylated  Smad2  (pSmad2),
CTGF,  and  α-SMA.  Rabbit
subconjunctival  fibroblasts  were
incubated  with  TGF-β2  and  various
concentrations  of  SB-505124.
SB-505124  effectively  reduced  the
pSmad2  level  and  the  expression  of
CTGF and α-SMA induced by TGF-β2
in  a  concentration-dependent  fashion.
SB-505124  was  effective  when  its
concentration  reached  1  µM,  and  the
expression of CTGF and α-SMA at 3
and 10 μM of concentrations is below
that  in  cells  without  the  TGF-β2
stimulation. The blots were also probed
for  Smad2,  β-actin,  or  GAPDH.  The
band intensity of pSmad2, CTGF and α-
SMA  was  normalized  against  that  of
Smad2,  β-actin,  and  GAPDH,
respectively, and the ratios are shown.
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1883NZW rabbits were anesthetized by subcutaneous injection of
a combination of medetomidine (approximately 0.25–0.5 mg/
kg; Pfizer Animal Helath, New York, NY) and ketamine (15
−20 mg/kg; Fort Dodge Animal Health, Fort Dodge, IA).
Additional injections (one fourth to one half of the original
dose) were also given every 30 to 45 min for maintenance.
Local anesthesia was provided with proparacaine HCl (0.5%
eye drops; Alcon, Fort Worth, TX). After washing the eye for
surgery  with  providone-iodine  topical  antiseptics  (1:16
dilution  with  sterile  water;  Aplicare,  Meriden,  CT),  all
procedures were performed under sterile conditions. For the
surgery,  the  eyelids  were  retracted  using  a  speculum.  A
partial-thickness corneal traction suture (8–0 silk; Alcon) was
placed in the superior cornea to rotate the eye inferiorly. A
clear corneal paracentesis tract was made between the 12 and
2 o’clock positions, and Viscoelastic material (0.1–0.2 ml,
Discovisc®; Alcon) was injected into the anterior chamber to
maintain  chamber  form.  Surgery  was  performed  at  the
anterior, temporal and superior sites of eyes. A fornix-based
conjunctival  flap  was  raised  behind  the  limbus.  A  scleral
tunnel to the corneal stroma was then fashioned. A 22-G/25-
mm venflon 2 cannula (Becton Dickinson, Franklin Lakes,
NJ) was passed through the sclera until it was visible in the
cornea. After entry of the cannula into the anterior chamber,
the cannula was fixed to the scleral surface with a 10–0 nylon
suture  (Alcon).  The  conjunctival  incision  was  closed  by
interrupted and mattress sutures using 9–0 nylon with taper
cut needle (Ethicon, Somerville, NJ). One drop of 1% atropine
and  a  single  application  of  combined  neomycin  and
dexamethasone ointment were applied to the ocular surface at
the end of surgery.
GFS with MMC treatment was performed as a control
(MMC  control).  Surgical  sponges  immersed  with  0.04%
MMC (Bedford Laboratories, Bedford, OH) were applied in
the subconjunctival space at the surgical site for 5 min right
after a fornix-based conjunctival flap was raised. The site was
then washed with 500 ml of balanced salt solution.
Delivery  of  SB-505124:  Tablets  containing  5  mg  of
SB-505124 and 65 mg lactose (6 mm in diameter, 1.0 mm in
thickness)  were  prepared  using  a  compression  technique
[43]. Prior to sutures of the conjunctival incision in GFS, the
lactose tablet was placed on the sclera at the surgical site after
being broken into several pieces. GFS without any adjuncts
(no adjunct control) and GFS with lactose tablets devoid of
inhibitors (tablet control) were used as controls.
Eye examination after GFS: All animals were examined by
slit-lamp daily during the first week after GFS, and at least
twice a week thereafter until the time of an occurrence of bleb
failure or post surgical infection, or up to 28 days post surgery.
Filtering  bleb,  anterior  chamber  activity  and  depth,
conjunctival hyperemia, and aqueous humor leakage were
examined. Bleb failure was defined as the appearance of a flat,
vascularized, scarred bleb in association with a deep anterior
chamber. The lack of aqueous humor drainage into the bleb
promoted by eye massage assisted in the judgment of bleb
Figure 4. Immunofluorescence staining for CTGF and α-SMA in subconjunctival fibroblasts. Immunoreactive products were visualized with
Alexa Fluor (green) labeling. Nuclei were stained with DAPI (blue). Rabbit subconjunctival fibroblasts were treated with or without TGF-
β2 and/or SB-505124. A dramatic increase in staining for TGF- β2-induced proteins CTGF and α-SMA was observed following TGF-β2
incubation. The staining intensity of these proteins was markedly reduced when cells were treated concomitantly with SB-505124. The cell
density was not affected by SB-505124 treatment. Bar, 50 µm.
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1884failure. Filtering blebs were also photographed with a digital
camera (FinePix F40fd; Fujifilm, Tokyo, Japan).
IOP in both treated and non-surgically-treated eyes was
measured with a TONO-PEN AVIA® (Reichert Ophthalmic
Instruments, Depew, NY) by gently touching the cornea after
topical anesthesia with 0.5% proparacaine at least twice a
week until the time of an occurrence of bleb failure or post
surgical infection, or up to 28 days post surgery. The IOP
reading was omitted if its confidence interval was less than
95%. An average of three measurements was taken to deduce
IOP.
Histological  examination  and  immunofluorescence:  Five
days after surgery, rabbits were euthanized with Fatal-plus™
(Vortech  Pharmaceutical,  Dearborn,  MI)  following
manufacturer’s  instructions.  Rabbit  eyes  were  enucleated
with palpebral margins to keep conjunctiva epithelium and
subconjunctival space intact. Enucleated eyes were fixed with
10% buffered formalin, and 5 μm thick paraffin sections were
prepared. The sections were stained with hematoxylin and
eosin (H&E) for histological examination. For fluorescence
staining, the sections were incubated at room temperature with
goat anti-CTGF (1:50) followed by Alexa Fluor 594 rabbit
anti-goat IgG (1:100; Invitrogen) and with mouse anti-α-SMA
(1:100) followed by DyLight 488 goat anti-goat IgG (1:100;
Jackson ImmunoResearch). Images were captured using an
Olympus  DX51  microscope  and  DP  controller  (Olympus,
Tokyo, Japan).
Subconjunctival  tissue  fibroblast  outgrowth  assay:  To
investigate if the efficacy of ALK-5 inhibitor in suppression
of  ocular  scarring  is  related  to  its  toxicity  like  MMC,  a
subconjunctival  tissue  fibroblast  outgrowth  assay  was
performed [44]. Five days after GFS with inhibitor or MMC,
rabbits  were  euthanized  as  described  above.  Under  an
ophthalmic surgical microscope, subconjunctival tissues were
dissected from the surgical site and 180° (6-o’clock position)
from the surgical site (180° control). Each biopsy specimen
was placed in a 25 cm2 cell culture flask with complete media.
Care was taken in handling the biopsy specimens, in particular
to ensure that the samples did not dry out and affect the cellular
viability. The cell outgrowth from each explant was observed,
and the length of the outgrowth in 4 quadrants was measured.
Statistical analysis: Bonferroni multiple comparison was used
to analyze cell numbers treated with SB-505124 and MMC
treatments  in  vitro.  Two-way  ANOVA  was  performed  to
evaluate  the  fibroblast  outgrowth  from  subconjunctival
tissues. The Kaplan–Meier method was used to analyze bleb
survival, and the samples that had post surgical infection were
treated as censoring in the method. All statistical analyses
were conducted by SPSS (ver.16; Chicago, IL).
RESULTS
Interaction between SB-505124 and ALK-5: To explore the
interaction or binding of SB-505124 with ALK-5, we docked
SB-505124 into the ATP/ligand binding pocket of ALK-5
Figure 5. Appearance of filtering blebs after glaucoma filtration surgery (GFS). The first row; GFS with SB-505124, the second row; MMC
control, the third row; no adjunct control and the bottom row; tablet control. In rabbits that received GFS with SB-505124 or MMC treatment,
filtering blebs were maintained for 1 week after GFS and beyond whereas blebs in the no adjunct and tablet controls failed within 1 week.
The blebs treated with SB-505124 failed by 3 weeks after surgery while the blebs in the MMC control were maintained.
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1885(Protein data bank access code 1VJY) [45]. As can be seen
from  Figure  1,  hydrogen  bond  interaction  appears  to  be
between SB-505124 and amino acid residues His-283 and
Ser-280 of ALK-5 (Figure. 1), which is located at the ATP
binding site in the intracellular ALK-5 kinase domain [46].
This binding mode of SB-505124 with ALK-5 appears to be
similar to that of the co-crystallized ligand of 1VJY [45], a
human expressed ALK-5 protein crystal. A water molecule is
seen forming a hydrogen-bonding bridge between SB-505124
and amino acid residues Asp-351, Glu-245 and Tyr-249.
SB-505124 impairs Smad2 phosphorylation and CTGF and
α-SMA  expression  in  vitro:  With  or  without  TGF-β2,
SB-505124 treatment for 48 h did not result in cell loss while
MMC treatment caused a significant (p<0.05) reduction in cell
number (Figure 2). Western blotting for pSmad2, CTGF, and
α-SMA  was  performed  to  examine  the  effect  of  ALK-5
inhibitor SB-505124 on downstream effects induced by TGF-
β2. The levels of pSmad2, CTGF, and α-SMA were found to
be reduced in a concentration-dependent fashion (Figure 3).
The band intensity for each protein in samples treated with
inhibitor was lower than that without inhibitor treatment under
TGF-β2  stimulation.  The  reduction  in  protein  levels  was
observed when the inhibitor concentration reached 1 μM, and
the reduction of CTGF and α-SMA levels was found to be
Figure  6.  Survival  curves  of  filtering
blebs after glaucoma filtration surgery
(GFS). Filtering blebs in the no adjunct
(n=5) and the tablet (n=5) controls failed
within  1  week.  Treatment  with
SB-505124  (n=5)  markedly  increased
the bleb survival period. In the MMC
control  (n=5),  three  blebs  survived
during the observation period, but post
surgical infection occurred in filtering
blebs of the remaining two on days 19
and 26, which are indicated by circles.
A  Kaplan–Meier  analysis  showed  a
significant  difference  in  the  survival
distributions  among  the  four
comparison  groups  (log  rank=25.688,
p<0.01).
Figure  7.  Intraocular  pressure  (IOP)
after glaucoma filtration surgery (GFS).
IOP  measurements  after  GFS  in  a
typical  case  of  each  treatment  group,
i.e., no adjunct control, tablet control,
GFS with SB-505124 and MMC control
groups, are shown. The lowest IOP was
noticed on post-GFS day 2 or 3 in each
case. IOP in the no adjunct control and
tablet  control  groups  exceeded
10  mmHg  before  week  1  and
subsequently plateaued. IOP in the GFS
with  SB-505124  groups  exceeded
10 mmHg before week 2. IOP in the
MMC  control  is  relatively  low
throughout the observation period. The
IOP readings seem to be related to bleb
survival in each case. Arrows indicate
the occurrence of bleb failure.
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By immunocytofluorescence, a dramatic increase in staining
for  CTGF  and  α-SMA  was  observed  following  TGF-β2
incubation  (Figure  4).  The  staining  intensity  of  TGF-β2-
induced proteins was greatly reduced when cells were treated
concomitantly with SB-505124.
Bleb survival and IOP reduction after GFS in rabbit model:
Bleb appearance after GFS and survival curves of blebs are
shown in Figure 5 and Figure 6, respectively. On post surgery
day 1, large filtering blebs were observed in all treated eyes.
A flat or shallow anterior chamber was seen in four of five
eyes in SB-505124 and MMC groups and one of five eyes in
no adjunct control group, but aqueous humor leakage was not
detected in any cases by the Seidel test. The filtering blebs in
the GFS with SB-505124 group were maintained for more
than 10 days without any severe postoperative complications,
and the blebs were clearly observed. In the MMC control
group, three of five blebs survived during the observation
period, while post surgical infection occurred in filtering blebs
of the remaining two on days 19 and 26. Blebs in the no
adjunct and tablet controls failed within 1 week. A Kaplan–
Meier analysis showed a significant difference in the survival
distributions  among  the  four  comparison  groups  (log
rank=25.688, p<0.01).
IOP measurements from a typical case in each rabbit
group and the average IOP after GFS are shown in Figure 7
and Table 1, respectively. In all treatment or control groups,
the average IOP on day 1 after GFS was lower than 10 mmHg.
The IOP was lower than 10 mmHg at week 1 in SB-505124
and MMC groups whereas it exceeded 10 mmHg at week 1
and thereafter in no adjunct and tablet controls. The IOP in
SB-505124 group exceeded 10 mmHg at week 2. IOP in the
MMC control group was relatively low throughout the entire
observation period. The IOP readings after GFS seemed to
reflect bleb survival in each group.
Histological  examination  and  immunofluorescence:  As
shown with H&E staining (Figure 8), infiltration of only a few
inflammatory cells and slight scarring were observed in the
subconjunctival space of eyes in the GFS with SB-505124 and
the  MMC  control  groups.  By  contrast,  numerous
inflammatory cells and massive scarring were seen in the no
adjunct  control.  At  the  limbus,  infiltration  of  cells  was
observed in all types of GFS. The conjunctival epithelium
appeared to be thinner in the MMC control group compared
to that in the GFS with SB-505124 and the no adjunct control
groups. Subconjunctival blood vessels were noted in the GFS
with SB-505124 and the no adjunct control groups, but seldom
in the MMC controls. Diffuse immunofluorescence staining
for  both  CTGF  and  α-SMA  was  detected  in  cells  at
subconjunctival area in the no adjunct controls. The staining
was weaker and scarce in the SB-505124 and MMC groups
(Figure 9).
TABLE 1. AVERAGE OF IOP AFTER GFS IN EACH GROUP.
GFS group Day 1 Week 1 Week 2 Week 3 Week 4
No adjunct control 8.2±1.0 (4) 12.1±1.2 (5) 10.3±1.6 (4) 11.3±0.6 (3) 12.0±0.3 (3)
Tablet control 9.7±1.3 (5) 10.1±0.4 (5) 10.2±2.0 (4) 11.5±0.7 (2) 13.0±0.0 (2)
SB-505124 5.0±4.6 (5) 4.5±4.6 (5) 13.2±3.3 (4) 12.8±3.5 (2) 13.0±1.9 (2)
MMC control 4.5±4.4 (5) 8.0±1.5 (5) 9.4±2.0 (5) 10.6±0.9 (4) 9.6±1.1 (4)
          Average±standard deviation of IOP (mmHg) was shown at each time point. Sample numbers were shown in parentheses.
Figure 8. Hematoxylin and eosin staining in tissue sections from eyes five days after surgery. Infiltration of only a few inflammatory cells
and mild scarring were observed in the subconjunctival space of eyes in the GFS with SB-505124 (left panel) or the MMC control (center
panel) group, whereas numerous inflammatory cells and massive scarring were seen in the no adjunct controls (right panel). At the corneal
limbus, infiltration of cells was observed in all 3 groups. Thinner conjunctival epithelium was seen in the MMC control compared to that in
the GFS with SB-505124 and no adjunct control groups. Subconjunctival blood vessels were noted in GFS with SB-505124 and no adjunct
control groups in general, but seldom in the MMC control group. Arrows indicate the conjunctival epithelium; double arrow, the limbus;
arrowhead, the subconjunctival blood vessel; asterisk, the subconjunctival space; and S, the sclera. Bar, 200 μm.
Molecular Vision 2010; 16:1880-1892 <http://www.molvis.org/molvis/v16/a204> © 2010 Molecular Vision
1887Subconjunctival fibroblast outgrowth assay: Cell outgrowth
from the subconjunctival tissue from GFS eyes treated with
SB-505124 was robust while it was poor from those treated
with MMC (Figure 10). There was no significant difference
in cell outgrowth between subconjunctival tissues treated with
SB-505124  and  the  180°  controls  whereas  a  significant
difference was noted between MMC and controls (p<0.01, 2-
way ANOVA, Figure 11). A few small, round specks that
appeared to be dead cells were noted on top of the outgrowth
from tissues treated with inhibitor and MMC, but seldom in
that from the 180° control tissues.
DISCUSSION
The present study demonstrates the efficacy of an ALK-5
inhibitor, SB-505124, in the possible treatment of filtration
surgery in glaucoma. SB-505124 is shown to block TGF-β-
mediated  induction  of  pSmad2,  CTGF,  and  α-SMA  in
cultured  rabbit  subconjunctival  fibroblasts  in  a  dose-
dependent  fashion  by  both  western  blotting  and
Figure 9. Immunofluorescence for CTGF and α-SMA in tissue sections from eyes five days after glaucoma filtration surgery (GFS). The top
row; immunofluorescence staining for CTGF (red), the bottom row; immunofluorescence for α-SMA (green). Diffuse subconjunctival cell
staining for both CTGF and α-SMA was observed in the no adjunct control while weaker and more scarce staining was demonstrated in the
SB-505124 and MMC groups. The weaker and less staining seems due to suppression of CTGF/α-SMA expression in the SB-505124 group.
In the MMC group, it is based on a lower cell number. Arrows indicate the conjunctival epithelium; asterisk, the subconjunctival space; S,
the sclera; arrowhead, blood vessel with red blood cells; and double arrowhead, non specific staining. Bar, 100 μm.
Figure 10. Fibroblast outgrowth from subconjunctival tissues. Five days after GFS, subconjunctival tissues were dissected, and each biopsy
specimen was placed in a 25 cm2 cell culture flask with complete media. Image of fibroblast outgrowth from subconjunctival tissues at day
10 in culture is shown. Cell outgrowth from explants of the GFS with SB-505124 (left panel) and the 180° control (right panel) groups is
robust whereas outgrowth is poor from that of the MMC control group (center panel). A few small, round specks that appeared to be dead
cells were found on top of the outgrowth from tissue treated with inhibitor and MMC, but seldom in that from the 180° control tissues. This
suggests that, while its toxicity is vastly reduced compared to MMC, 5 mg of SB-505124 delivered within a lactose tablet is not entirely
nontoxic.
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1888immunofluorescence staining inhibition. The inhibition effect
is observed when the inhibitor concentration reaches 1 μM.
The expression of downstream proteins in cells treated with 3
and 10 μM of the inhibitor is below that in cells without the
TGF-β2 stimulation, suggesting that 3 μM of SB-505124 is
sufficient to block the TGF-β2 function. Our docking studies
indicate that the affinity of SB-505124 with ALK-5 is likely
due to hydrogen bonding between the two molecules, similar
to other ALK-5 kinase inhibitors [47].
In a previous paper, SB-505124 was reported to be a
potent inhibitor of the in vitro kinase activity of ALK-5 for its
substrate Smad3 with an IC50 of 47±5 nM [37], which is much
lower  than  the  effective  concentration  in  our  study.  The
disparity may be related to differences in cell types, species,
experimental methods and parameters studied.
The  TGF-β  pathway  implicated  in  scarring  has  been
investigated as an approach to reduce severe post-surgical
complication caused by GFS with MMC. While promising
preliminary results had been obtained, a monoclonal antibody
for  TGF-β2  (CAT-152)  failed  to  achieve  significant
improvement  in  preventing  the  failure  of  primary
trabeculectomy in human glaucoma eyes [28]. It is speculated
that CAT-152 might have been underdosed [28]. Recently,
another ALK-5 inhibitor, SB-431542, was reported to be able
Figure  11.  Line  graph  for  cell
outgrowth. For each of the GFS with
SB-505124  or  MMC  groups,
subconjunctival tissues were dissected
from eyes of two rabbits that underwent
GFS  five  days  after  surgery.  Three
pieces  of  subconjunctival  tissue  were
dissected from the surgical site and 180°
(6-o’clock position) from the surgical
site (180° control). The cell outgrowth
from each explant was observed, and the
length of the outgrowth from the explant
in four quadrants was measured. While
a significant difference was observed in
cell  growth  between  the  surgical  site
specimen and the 180° control (p<0.01,
2-way  ANOVA)  in  GFS  with  MMC,
there was no significant difference in
that  with  SB-505124.  Bars  indicate
standard deviation.
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1889to abrogate TGF-β induced upregulation of α-SMA, CTGF
and collagen type I at concentrations of 1–20 μM in vitro
[41]. However, subconjunctival injection of 0.1 ml of 0.5 or
2 mM SB-431542 immediately after the surgery and on days
1, 2, 3, and 7 after surgery did not result in longer survival of
filtering blebs although the conjunctiva was more translucent
compared to controls.
During the initial phase of our study, we examined several
ALK-5  inhibitors,  including  616451  [36],  616452  [38]
(Calbiochem, San Diego, CA), A-83–01 [40], SB-431542
[34], SB-505124 [37], and SB-525334 (Sigma) [48] in rabbit
GFS.  These  inhibitors  were  delivered  by  subconjunctival
injection of 0.1 ml solution with up to 300 μM concentration
(during surgery and twice a day up to 5 day after surgery) and
by tablet placement containing 1 mg of a given inhibitor. Only
a slight improvement was observed with the use of tablets
containing  SB-505124  (data  not  shown).  In  subsequent
experiments, 5 mg of SB-505124 was tested, and successfully
improved bleb survival. The dosage of the inhibitor used thus
seems to be of crucial importance.
By  H&E  staining,  the  conjunctival  epithelium  and
subconjunctival  blood  vessels  in  GFS  eyes  treated  with
SB-505124  appear  undamaged,  similar  to  that  in  the  no
adjunctive controls. Infiltration of a few inflammatory cells
and mild scarring were observed. In the MMC control group,
infiltration and scarring were also at a low level, but the
conjunctival epithelium became thinner and few blood vessels
were  seen.  Additionally,  the  subconjunctival  fibroblast
outgrowth  assay  revealed  that  the  cell  outgrowth  from
subconjunctival tissues treated with SB-505124 was much
more robust compared to that from tissues treated with MMC.
Meanwhile, suppression of CTGF and α-SMA by SB-505124
after GFS was observed by immunofluorescence. Overall, our
results  indicate  that  SB-505124  is  able  to  suppress
subconjunctival scarring, via blocking of the TGF-β activity,
in an in vivo rabbit model without much tissue damage and
with vastly reduced toxicity compared to MMC.
In some cases, especially in the no adjunct control and
tablet control groups, IOP reduction in operated eyes was
limited, and IOP in the early post surgery period was higher
than  that  in  other  reports  [41].  In  our  GFS,  viscoelastic
material was injected into the anterior chamber to maintain
chamber form during surgery. Therefore, even in the early
post-surgical period, for example day 1 after GFS, dramatic
IOP reduction was not seen in all cases (Figure 9) presumably
because  of  the  viscoelastic  material  that  remained  in  the
anterior chamber.
Our  data  also  showed  that  while  bleb  survival  was
improved by SB-505124, the survival period was shorter that
that produced by MMC. It is speculated that maintaining an
appropriate concentration of SB-505124 in the filtering bleb
may be the key to extend the period of bleb survival. Further
investigation employing a controlled drug delivery system
needs to be conducted.
In summary, the current study demonstrates that blocking
the  TGF-β  signaling  pathway  by  local  application  of
SB-505124 prevents ocular scarring after GFS. Our results
underscore the potential of a novel therapy for GFS and for
preventing the inflammatory response and scarring in ocular
diseases. This approach may also have applications for other
surface tissues, including the skin.
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